Industry Contacts

Big Pharma

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives. Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). We are also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. We operate in more than 100 countries and our innovative medicines are used by millions of patients worldwide. We want to be valued as a source of great medicines and trusted as a company that delivers business success responsibly. We are committed to operating with integrity and high ethical standards across all our activities. We push the boundaries of science to deliver life-changing medicines.

Fresenius Medical Care
More than three decades of experience in dialysis, innovative research, the global leader in dialysis services and products – that is Fresenius Medical Care. Patients with kidney disease can now look ahead with much more confidence thanks to our innovative technologies and treatment concepts. We give them a future, one that offers them the best-possible quality of life. We use the increasing demand for modern dialysis methods to our advantage and work consistently to enhance the Company’s growth. Together with our employees, we focus on pursuing strategies that will enable us to uphold our technological leadership. As a vertically integrated company, we offer products and services for the entire dialysis value chain. The highest medical standards are our benchmark. This is our commitment to our patients, our partners in the healthcare system and our investors, who trust in the reliable performance and the future of Fresenius Medical Care.

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.


BioRenovo is a private Regenerative Medicine Company whose mission is to secure external funding for regenerative-medicine projects currently running at The Mario Negri Institute for Pharmacological Research. Projects selected have passed the 'proof of concept' stage and have treating or therapeutic potential. Project proposals submitted to investors, aim to take the project from lab-to-market, or to a next funding phase that can also constitute an investor exit point. Projects BioRenovo are currently promoting attempt to provide breakthrough therapies to patients suffering from kidney failure, thereby resolving, or at least alleviating the global need for dialysis or organ transplantation, as well as other associated problems, such as anaemia caused by EPO inefficiency.

Orbsen Therapeutics
Orbsen Therapeutics Ltd is a privately held company and was originally founded in 2006 as a spin out from , Ireland's Regenerative Medicine Institute (REMEDI) in NUI Galway. Since then, Orbsen has developed proprietary technologies (ORB1) that enables the isolation of pure and therapeutic stromal cells from human tissues. These therapeutic (ORB1+) cells can purified from a single donor, expanded and frozen to generate many doses of a high-margin, “off-the-shelf” therapeutic product for indications with unmet need.

Biotech company specialized in providing products for Research: human cells, 3D models of tumors (Spheroïds) and biomaterials.

ImmunoTools provides you more reagents for your budget. Our mission: Excellent quality - advantageously priced.

ReGenesys is an affiliate of Athersys, a publicly held biotechnology company located in Cleveland, Ohio (NASDAQ: ATHX). The company is focused on the research and development of stem cell therapies to address unmet needs, and conducts basic and applied research related to product characterization, performance and manufacturing. Additionally, ReGenesys has responsability for European development of MultiStem® cells for the treatment of certain diseases.

Cellec Biotek AG
CELLEC BIOTEK AG was founded as a spin-off of a lab of University Hospital Basel, Switzerland, active in the world of Tissue Engineering and Regenerative Medicine. We are an international team of engineers, biotechnologists and clinicians. We develop and commercialize bioreactors for 3D cell culture and tissue generation. Our products allow growing 3D living tissues, as advanced model systems for tissue development and drug testing, applied to life sciences and pharmaceutical research, and potentially as biological grafts for tissue and organ regeneration, applied to clinical translation in regenerative medicine.

SpheriTech specialises polymer and particle design supporting a range of industries including peptide synthesis, oligonucleotide synthesis, biocatalysis, cell culture, tissue regeneration, wound dressings and all aspects of chromatography.

We carefully select the best analytical platforms to offer customized RNA (mRNA, miRNA, and lncRNA) gene expression services. Our service lab activities support the life science market at every level of the entire process: from discovery to validation of biomarkers, from optimal experiment design to extensive analysis and interpretation of results, from PCR assay design to research-use-only kits. We have a wide range of references in the academic, top research and industrial market. We established expertise in the discovery, validation, and stability monitoring of biomarkers. Our core expertise is to design specific assays and to validate these in our lab. We can also provide assay audits in order to streamline and enhance your current workflow. Biogazelle is at the forefront of digital PCR based research as it was one of the first European laboratories that had access to the technology. Furthermore Biogazelle has an agreement with Bio-Rad to act as a reference center for the QX100 digital droplet PCR (ddPCR) system in Europe. This is completely in line with Biogazelle's mission to address unmet needs through excellence in science and technology.

Glomega Inc.
Glomega Inc. is a Life Science company focused on biomarker based molecular diagnostics of diabetes. Our mission is to develop and commercialize early stage tests for diabetes and its complications and effective personalized management of diabetes with novel diagnostic platforms and lower overall healthcare costs.

Xpand Biotechnology
The mission of Xpand Biotechnology BV is to develop innovative technologies in the area of cell cultivation (bioreactor) and regenerative medicine (calcium phosphate-based materials). Xpand’s bioreactor system enables clinical scale cell cultivation in a controlled environment and provides a cost effective alternative to 2D cell growth in tissue culture flasks or cell stacks. Xpand’s instructive calcium phosphate-based materials allow the induction of specific tissue formation such as bone and cartilage without the need for adding stem cells or growth factors.